Reading and Resources
Clinical practice guidelines and recommendations
- AAAI Clinical Management Review: The Clinical Approach to Chronic Cough
- AAAI evidence-based, and expert opinion recommendations: Yardstick for managing cough, part 1
- ACCP guidelines on treatment of unexplained chronic cough
- AAFP: Chronic Cough: Evaluation and Management
- Classification of Cough as a Symptom in Adults and Management Algorithms: CHEST Guideline and Expert Panel Report
- ERS guidelines on the diagnosis and treatment of chronic cough in adults and children
- WAO-ARIA consensus on chronic cough – Part III: Management strategies in primary and cough-specialty care
- Guidelines
Review articles on refractory chronic cough and emerging therapies
- Current opinion in refractory and/or unexplained chronic cough
- Interdisciplinary collaboration in the diagnosis and management of chronic cough: the role and importance of primary care providers
- Management of Refractory Chronic Cough and Emerging Therapies in 2025
- Mechanistic insights into the selective targeting of P2X3 receptor by camlipixant antagonist
- Refractory Chronic Cough: A State-of-the-Art Review for Otolaryngologists
- The Past, Present, and Future Care for Refractory Chronic Cough in Children and Adults
- Unexplained or Refractory Chronic Cough in Adults
- Update on Speech Pathology Management of Chronic Refractory Cough
Clinical trial results for emerging therapies
P2X3 antagonists
- Camlipixant in Refractory Chronic Cough: A Phase 2b, Randomized, Placebo-controlled Trial (SOOTHE)
- Design of the landmark CALM-1 AND CALM-2 PHASE 3 clinical trials of camlipixant in refractory chronic cough
- Efficacy and safety of gefapixant, a P2X3 receptor antagonist, in refractory chronic cough and unexplained chronic cough (COUGH-1 and COUGH-2): results from two double-blind, randomised, parallel-group, placebo-controlled, phase 3 trials
- Efficacy and Safety of Eliapixant in Refractory Chronic Cough: The Randomized, Placebo-Controlled Phase 2b PAGANINI Study
- Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Phase 2b Trial of P2X3 Receptor Antagonist Sivopixant for Refractory or Unexplained Chronic Cough
- Systematic review: Benefit-Risk Profile of P2X3 Receptor Antagonists for Treatment of Chronic Cough
Other emerging therapies
- IPF COMFORT Study: A randomised, controlled trial evaluating the safety and efficacy of orvepitant as a treatment for chronic cough in IPF
- Nalbuphine Tablets for Cough in Patients with Idiopathic Pulmonary Fibrosis
- Neurokinin-1 Receptor Antagonist Orvepitant Is a Novel Antitussive Therapy for Chronic Refractory Cough: Results From a Phase 2 Pilot Study (VOLCANO-1)
Patient education
- Chronic cough
- How To Stop an Asthma Cough
- Chronic cough
- My cough interferes with everything’: New research could help refractory chronic cough patients after decades of depression, pain, and sleep loss
- Postnasal Drip
- Pulmonary function testing
- What Is an Allergy Cough and How Do I Get Over It?
- When the Coughing Won’t Stop
- Why acid reflux cough happens and how to treat it
- Resources
All URLs accessed March 9, 2026
